PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för (S)-warfarin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

17 hits

Bibliografisk träff 2023-12-01

Exploring the complex relationship between vitamin K, gut microbiota, and warfarin variability in cardiac surgery patients.

Xue L, Singla RK, Qin Q, Ding Y, Liu L, Ding X, Qu W, Huang C, Shen Z, Shen B, Miao L.

Int J Surg · research-article; journal article · DOI 10.1097/js9.0000000000000673

Bibliografisk träff 2023-03-13

Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.

Lee W, Kim MS, Kim J, Aoki Y, Sugiyama Y.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.122.000968

Bibliografisk träff 2022-07-07

<b>Pharmacokinetic Modeling of Warfarin І - Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals <i>CYP2C9</i> Genotype-dependent Drug-drug Interactions of S-Warfarin</b>.

Cheng S, Flora DR, Rettie AE, Brundage RC, Tracy TS.

Drug Metab Dispos · research-article; journal article · DOI 10.1124/dmd.122.000876

Bibliografisk träff 2022-06-14

Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.

Shaul C, Blotnick S, Adar L, Muszkat M, Bialer M, Caraco Y.

Clin Pharmacokinet · journal article · DOI 10.1007/s40262-022-01141-2

Bibliografisk träff 2022-05-05

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.

Wanounou M, Shaul C, Abu Ghosh Z, Alamia S, Caraco Y.

Clin Pharmacol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cpt.2613

Bibliografisk träff 2021-09-24

Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin.

Henderson LM, Steinbronn CE, Yu J, Yeung CK, Ragueneau-Majlessi I.

Clin Ther · systematic review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.clinthera.2021.08.016

Bibliografisk träff 2021-03-23

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.

Tran L, Nikanjam M, Capparelli EV, Bertino JS, Nafziger AN, Kashuba ADM, Turpault S, Ma JD.

Eur J Clin Pharmacol · journal article · DOI 10.1007/s00228-021-03123-y

Bibliografisk träff 2020-10-29

Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3).

Shiozawa A, Yamaori S, Kamijo S, Ohmori S.

Drug Metab Pharmacokinet · journal article · DOI 10.1016/j.dmpk.2020.10.003

Bibliografisk träff 2020-08-01

Correction to "Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers".

Författaruppgift saknas

Drug Metab Dispos · published erratum; journal article · DOI 10.1124/dmd.120.000141

Bibliografisk träff 2020-05-19

Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin.

Fujii M, Yasuda K, Sakaki T.

Drug Metab Pharmacokinet · journal article · DOI 10.1016/j.dmpk.2020.05.002

Bibliografisk träff 2018-02-20

Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation.

Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, Varma MVS.

Mol Pharm · journal article · DOI 10.1021/acs.molpharmaceut.7b01108

Bibliografisk träff 2015-07-01

Determination of S- and R-warfarin enantiomers by using modified HPLC method.

Qayyum A, Najmi MH, Khan AM, Abbas M, Naveed AK, Jameel A.

Pak J Pharm Sci · research support, non-u.s. gov't; journal article

Bibliografisk träff 2014-07-24

Fast separation of warfarin and 7-hydroxywarfarin enantiomers by cyclodextrin-assisted capillary electrophoresis.

Nowak P, Garnysz M, Woźniakiewicz M, Kościelniak P.

J Sep Sci · research support, non-u.s. gov't; journal article · DOI 10.1002/jssc.201400514

Bibliografisk träff 2014-01-01

A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma.

Ju W, Peng K, Yang S, Sun H, Sampson M, Wang MZ.

Austin J Anal Pharm Chem · research-article; journal article

Bibliografisk träff 2012-01-01

[Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study].

Jin S, Zhang YF, Chen XY, Liu K, Zhong DF.

Yao Xue Xue Bao · research support, non-u.s. gov't; journal article

Bibliografisk träff 2010-11-25

Metabolic profiling of HepG2 cells incubated with S(-) and R(+) enantiomers of anti-coagulating drug warfarin.

Bai J, Wang MX, Chowbay B, Ching CB, Chen WN.

Metabolomics · research-article; journal article · DOI 10.1007/s11306-010-0262-3

Bibliografisk träff 1980-03-01

Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man.

O'Reilly RA, Trager WF, Motley CH, Howald W.

J Clin Invest · comparative study; research support, u.s. gov't, p.h.s.; research-article; journal article · DOI 10.1172/jci109722